Evidence map›Paper›PMID 21771881›Full record

ArticleJournal of cell science2011

The C-terminal tail of tetraspanin protein CD9 contributes to its function and molecular organization.

Hong-Xing Wang, Tatiana V Kolesnikova, Carilee Denison, Steven P Gygi, Martin E Hemler

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Trop-2, NaOncogene · 2022
    Article
  4. CD9, a tetraspanin target for cancer therapy?Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  5. Tetraspanin-enriched microdomains regulate digitation junctions.Cellular and molecular life sciences : CMLS · 2018
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Tetraspanins and cell membrane tubular structures.Cellular and molecular life sciences : CMLS · 2012
    Review
  13. Endothelial membrane reorganization during leukocyte extravasation.Cellular and molecular life sciences : CMLS · 2012
    Review
  14. Exosome mimetics: a novel class of drug delivery systems.International journal of nanomedicine · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hong-Xing WangDepartment of Cancer Immunology and AIDS, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
Tatiana V Kolesnikova
Carilee Denison
Steven P Gygi
Martin E Hemler
Harvard University · USDana-Farber Cancer Institute · US

Funding

TRANSMEMBRANE LINKER FUNCTIONS OF TM4SF PROTEINSR01GM038903 · NIGMS · DANA-FARBER CANCER INSTITUTE · PI HEMLER, MARTIN E · 1987 to 2011
$3.7M
NIGMS NIH HHS GM38903NIGMS NIH HHS R01 GM038903
6 · The paper itself

Abstract

Tetraspanin protein CD9 supports sperm-egg fusion, and regulates cell adhesion, motility, metastasis, proliferation and signaling. The large extracellular loop and transmembrane domains of CD9 engage in functionally important interactions with partner proteins. However, neither functional nor biochemical roles have been shown for the CD9 C-terminal tail, despite it being highly conserved throughout vertebrate species. To gain new insight into the CD9 tail, three C-terminal amino acids (Glu-Met-Val) were replaced with residues corresponding to C-terminal amino acids from tetraspanin protein CD82 (Pro-Lys-Tyr). Wild-type and mutant CD9 were then stably expressed in MOLT-4, K562, U937, RD and HT1080 cells. Whereas wild-type CD9 inhibited cell adhesion and spreading on fibronectin, mutant CD9 did not. Wild-type CD9 also promoted homotypic cell-cell aggregation and microvilli formation, whereas mutant CD9 did not. Protein interactions of wild-type and mutant CD9 were compared quantitatively using stable isotope labeling with amino acids in cell culture (SILAC) in conjunction with liquid-chromatography-tandem mass spectrometry (LC-MS/MS) technology. SILAC results showed that, despite wild-type and mutant CD9 having identical expression levels, mutant CD9 and its major transmembrane interacting partners were recovered in substantially reduced amounts from 1% Brij 96 lysates. Immunoprecipitation experiments confirmed that mutant CD9 recovery was decreased in Brij 96, but not in more stringent Triton X-100 detergent. Additionally, compared with wild-type CD9 complexes, mutant CD9 complexes were larger and more oligomerized in Brij 96 detergent, consistent with decreased Brij 96 solubility, perhaps due to more membrane domains packing more tightly together. In conclusion, multiple CD9 functions depend on its C-terminal tail, which affects the molecular organization of CD9 complexes, as manifested by their altered solubilization in Brij 96 and organization on the cell surface.

Indexed as

Cell AdhesionCell MovementHumansK562 CellsKangai-1 ProteinMutagenesis, Site-DirectedMutationProtein BindingProtein MultimerizationProtein Structure, QuaternaryProtein Structure, TertiaryTetraspanin 29TetraspaninsTransgenesU937 CellsKangai-1 ProteinTetraspanin 29Tetraspanins

Identifiers

PMID21771881
PMCPMC3148130
OpenAlexW2121273108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.